UK poised to announce booster COVID jabs for over-50sThe UK government is due to announce a large-scale booster vaccine campaign against COVID-19 for all adults aged Share XUK poised to announce booster COVID jabs for over-50shttps://pharmaphorum.com/news/uk-poised-to-announce-booster-covid-jabs-for-over-50s/
Zoll agrees $538m deal to buy sleep apnoea specialist ItamarItamar Medical was on the acquisition trail itself earlier this year, buying Spry Health to extend its sleep Share XZoll agrees $538m deal to buy sleep apnoea specialist Itamarhttps://pharmaphorum.com/news/zoll-agrees-538m-deal-to-buy-sleep-apnoea-specialist-itamar/
AbbVie spies potential in Regenxbio eye disease gene therapyAbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get Share XAbbVie spies potential in Regenxbio eye disease gene therapyhttps://pharmaphorum.com/news/abbvie-spies-potential-in-regenxbio-eye-disease-gene-therapy/
First FDA filing for Novartis’ latecomer PD-1 drug tislelizumabNovartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier Share XFirst FDA filing for Novartis’ latecomer PD-1 drug tislelizumabhttps://pharmaphorum.com/news/first-fda-filing-for-novartis-latecomer-pd-1-drug-tislelizumab/
NHS England starts largest ever trial of Galleri cancer blood testA blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will Share XNHS England starts largest ever trial of Galleri cancer blood testhttps://pharmaphorum.com/news/nhs-england-starts-largest-ever-trial-of-galleri-cancer-blood-test/
Valneva slumps as UK dumps €1.4bn order for COVID-19 jabThe UK has terminated its order for up to 190 million doses of a COVID-19 vaccine developed by Share XValneva slumps as UK dumps €1.4bn order for COVID-19 jabhttps://pharmaphorum.com/news/valneva-slumps-as-uk-dumps-e1-4bn-order-for-covid-19-jab/
Apellis reports mixed data with eye drug, but plans to file anywayApellis Pharma has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major Share XApellis reports mixed data with eye drug, but plans to file anywayhttps://pharmaphorum.com/news/apellis-reports-mixed-data-with-eye-drug-but-plans-to-file-anyway/
Digital health approach improves neurosurgery care, says studyDeployment of digital health technologies during the pandemic improved patient satisfaction, expanded the delivery of care and augmented Share XDigital health approach improves neurosurgery care, says studyhttps://pharmaphorum.com/news/digital-health-approach-improves-neurosurgery-care-says-study/
Biogen admits slow Aduhelm launch, as scientists question label againShares in Biogen have come under pressure after chief executive Michel Vounatsos admitted that the company is facing Share XBiogen admits slow Aduhelm launch, as scientists question label againhttps://pharmaphorum.com/news/biogen-admits-slow-aduhelm-launch-as-scientists-question-label-again/
